Target Validation Information
TTD ID T44011
Target Name Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)
Type of Target
Clinical trial
Drug Potency against Target Drug Info IC50 = 20 nM [5]
Drug Info IC50 = 46 nM [8]
Drug Info IC50 = 119 nM [8]
Drug Info IC50 = 717 nM [8]
1,1':4',1''-terphenyl-3,3''-diol Drug Info IC50 = 173 nM [8]
1,1':4',1''-terphenyl-3,4''-diol Drug Info IC50 = 471 nM [8]
1-Bromo-6-(3-hydroxyphenyl)-2-naphthol Drug Info IC50 = 40 nM [5]
16-(pyridin-4-yl)methylene-estradiol Drug Info IC50 = 4100 nM [1]
16-beta-ethoxymethyl-estrone Drug Info IC50 = 320 nM [1]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol Drug Info IC50 = 8 nM [8]
2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol Drug Info IC50 = 64 nM [8]
2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol Drug Info IC50 = 113 nM [8]
3'-(1-Benzothien-2-yl)biphenyl-3-ol Drug Info IC50 = 1370 nM [9]
3'-(5-Chloro-2-thienyl)biphenyl-3-ol Drug Info IC50 = 560 nM [9]
3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol Drug Info IC50 = 201 nM [7]
3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol Drug Info IC50 = 336 nM [7]
3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol Drug Info IC50 = 169 nM [7]
3,3'-(1,3-Thiazol-2,4-diyl)diphenol Drug Info IC50 = 455 nM [7]
3,3'-(3-Methylthiene-2,5-diyl]diphenol Drug Info IC50 = 567 nM [8]
3,3'-(3-Phenylthiene-2,5-diyl)diphenol Drug Info IC50 = 493 nM [8]
3,3'-pyrazine-2,5-diyldiphenol Drug Info IC50 = 1000 nM [7]
3,3'-Pyridine-2,5-diyldiphenol Drug Info IC50 = 101 nM [7]
3,3'-Thiene-2,4-diyldiphenol Drug Info IC50 = 185 nM [7]
3,3'-thiene-2,5-diyldiphenol Drug Info IC50 = 173 nM [8]
3,3-(1,3-Thiazole-2,5-diyl)diphenol Drug Info IC50 = 243 nM [7]
3,4'-(thiophene-2,4-diyl)diphenol Drug Info IC50 = 77 nM [8]
3-(2-naphthyl)phenol Drug Info IC50 = 2257 nM [2]
3-(5-phenyl-2-thienyl)phenol Drug Info IC50 = 342 nM [8]
3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol Drug Info IC50 = 42 nM [8]
3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol Drug Info IC50 = 2380 nM [9]
3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol Drug Info IC50 = 1610 nM [3]
3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol Drug Info IC50 = 1850 nM [3]
3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol Drug Info IC50 = 850 nM [9]
3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol Drug Info IC50 = 780 nM [8]
3-[5-(3-Fluorophenyl)-2-thienyl]phenol Drug Info IC50 = 535 nM [8]
3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol Drug Info IC50 = 310 nM [7]
3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol Drug Info IC50 = 50 nM [8]
3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol Drug Info IC50 = 629 nM [8]
3-[5-(4-hydroxyphenyl)-2-thienyl]phenol Drug Info IC50 = 69 nM [8]
3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol Drug Info IC50 = 151 nM [7]
3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol Drug Info IC50 = 1390 nM [9]
4'-(5-Chloro-2-thienyl)biphenyl-3-ol Drug Info IC50 = 1020 nM [9]
4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol Drug Info IC50 = 690 nM [9]
4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol Drug Info IC50 = 51 nM [8]
4-Methyl-1,1':4',1''-terphenyl-3,4''-diol Drug Info IC50 = 171 nM [8]
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol Drug Info IC50 = 402 nM [8]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol Drug Info IC50 = 64 nM [8]
5-(6-hydroxy-2-naphthyl)pyridin-3-ol Drug Info IC50 = 1232 nM [2]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 116 nM [5]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol Drug Info IC50 = 2425 nM [2]
6-oxo-estrone Drug Info IC50 = 340 nM [1]
APIGENIN Drug Info IC50 = 710 nM [4]
BVT.2733 Drug Info IC50 = 52 nM [6]
Ethyl estrone-16-methylcarboxylate Drug Info IC50 = 300 nM [1]
KAEMPFEROL Drug Info IC50 = 1050 nM [4]
N-(1'-Phenyl-ethyl) estradiol-16-carboxamide Drug Info IC50 = 810 nM [1]
N-(pyridin-3-ylmethyl) estradiol-16-carboxamide Drug Info IC50 = 510 nM [1]
N-methyl estrone-16-methyl carboxamide Drug Info IC50 = 1500 nM [1]
NARINGENIN Drug Info IC50 = 4960 nM [4]
NSC-94258 Drug Info IC50 = 5250 nM [4]
References
REF 1 Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45.
REF 2 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
REF 3 Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid ... Bioorg Med Chem. 2008 Jun 15;16(12):6423-35.
REF 4 Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
REF 5 Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
REF 6 Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. J Med Chem. 2008 Aug 28;51(16):4851-7.
REF 7 Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39.
REF 8 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
REF 9 Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.